Search results
The Motley Fool recommends Moderna Inc
- At roughly nine times its trailing-12-month sales and a healthy profitability and cash profile, Moderna looks like a good buy going into 2022. Adam Spatacco does not own shares of any of the companies mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.
www.fool.com/investing/2022/01/05/is-now-a-good-time-to-buy-moderna-stock/
People also ask
Is now a good time to buy Moderna stock?
Is Moderna a good buy in 2022?
Should Moderna buy Moderna?
What if I don't want to buy a full share of Moderna?
Is it advisable to invest in Moderna?
Is Moderna a good stock for patient buy-and-hold investors?
Jan 5, 2022 · Motley Fool Issues Rare “All In” Buy Alert. NASDAQ: MRNA. Moderna. Market Cap. $22B. Today's Change. (-0.56%) -$0.33. Current Price. $58.39. Price as of October 8, 2024, 4:00 p.m. ET. After...
Aug 23, 2021 · 2021 has been a fabulous year for the Moderna (NASDAQ: MRNA) share price, with it rising over 240% so far. This cements the stock as the top performer in the S&P 500 this year. But some people...
Nov 30, 2021 · Moderna (NASDAQ: MRNA) might be one of only a handful of companies that may benefit from the omicron virus. Indeed, Moderna stock rallied on Friday when news broke of this new Covid strain. The...
Jul 20, 2021 · So, as long as you're planning on holding Moderna for the long term, it's a good purchase right now. Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool...
Jul 29, 2021 · Moderna is riding high on the COVID-19 wave. Is it too late to get in? In response to the COVID-19 pandemic, many pharmaceutical companies around the world have raced to produce an effective...
Jun 13, 2022 · Moderna is expecting another good year, with $21bn in revenue forecast for 2022. However, demand for its key vaccine is certainly slowing. There were only $2.5bn of deals between January and...
Apr 1, 2024 · Jeff Santoro, The Motley Fool. Mon, Apr 1, 2024, 8:45 AM4 min read. In This Article: MRNA. Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna(NASDAQ: MRNA). At the...